The bill amends sections 3902.50 and 3902.70 of the Revised Code and enacts a new section 3902.72, which prohibits drug manufacturers from engaging in certain actions regarding the acquisition and delivery of drugs to 340B covered entities. Specifically, it prevents manufacturers, repackagers, and third-party logistics providers from denying or limiting the acquisition of 340B drugs by these entities, as well as from requiring them to submit claims or utilization data as a condition for drug acquisition. The bill also establishes definitions for terms related to the 340B drug pricing program and outlines penalties for violations, including civil penalties and potential referral to the state board of pharmacy.

Additionally, the bill includes provisions that require health plan issuers and pharmacy benefit managers to provide data related to drug coverage upon request, ensuring that this information is current, accessible, and not hindered by unnecessary restrictions. It emphasizes the importance of transparency in drug pricing and access, allowing healthcare providers to communicate relevant information to patients without interference. The new regulations are set to take effect on January 1, 2022, and existing sections 3902.50, 3902.70, and 3902.72 are repealed to accommodate these changes.

Statutes affected:
As Introduced: 3902.50, 3902.70, 3902.72, 3902.75